beta

ABUS

Arbutus Biopharma Corporation

Abus

Chart

Stats

Earnings

News

Splits

Dividends

Earnings

Actual EPS
Consensus EPS
Estimated EPS
Number of Estimates
EPS Surprise

Stats

Summary

Arbutus Biopharma Corp is a biopharmaceutical business engaged in advancing novel RNA interference therapeutics and discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection.

Market Cap: 292 Million

Primary Exchange: Nasdaq Global Select

Website: http://www.arbutusbio.com

Shares Outstanding: 55.6 Million

Float: 51 Million

Dividend: 0.0 (0.0%)

Beta: 1.128171

Sector: Healthcare

Industry: Biotechnology

Short Interest (Jan 12, 2018): 705 Thousand

Ethical Flags

Animal testing

Longest drawdown: 1410 trading days

From: 2014-03-11 To: 2019-10-11

Lowest Point:

Ex-Date Payment Date Record Date Declared Date Amount Flag Dividend Type Qualified Indicated
Ex-Date Declared Date Record Date Payment Date Ratio To Factor For Factor
Data provided by IEX Cloud